ES2159552T3 - Terapia de sustitucion de hormonas. - Google Patents

Terapia de sustitucion de hormonas.

Info

Publication number
ES2159552T3
ES2159552T3 ES94909721T ES94909721T ES2159552T3 ES 2159552 T3 ES2159552 T3 ES 2159552T3 ES 94909721 T ES94909721 T ES 94909721T ES 94909721 T ES94909721 T ES 94909721T ES 2159552 T3 ES2159552 T3 ES 2159552T3
Authority
ES
Spain
Prior art keywords
substitution therapy
hormone substitution
hormone
estrogen
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94909721T
Other languages
English (en)
Inventor
Gary D Hodgen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical College of Hampton Roads
Original Assignee
Medical College of Hampton Roads
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21816657&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2159552(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medical College of Hampton Roads filed Critical Medical College of Hampton Roads
Application granted granted Critical
Publication of ES2159552T3 publication Critical patent/ES2159552T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Dental Preparations (AREA)
  • Prostheses (AREA)
  • Materials For Medical Uses (AREA)

Abstract

UN METODO DE TERAPIA DE SUSTITUCION DE HORMONA INCLUYE LA ADMINISTRACION DE ESTROGENO JUNTO CON UNA CANTIDAD DE ANTIPROGESTINA QUE INHIBE LA PROLIFERACION ENDOMETRIAL INDUCIDA POR ESTROGENO EN UNA MUJER.
ES94909721T 1993-02-25 1994-02-18 Terapia de sustitucion de hormonas. Expired - Lifetime ES2159552T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/023,692 US5468736A (en) 1993-02-25 1993-02-25 Hormone replacement therapy

Publications (1)

Publication Number Publication Date
ES2159552T3 true ES2159552T3 (es) 2001-10-16

Family

ID=21816657

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94909721T Expired - Lifetime ES2159552T3 (es) 1993-02-25 1994-02-18 Terapia de sustitucion de hormonas.

Country Status (25)

Country Link
US (1) US5468736A (es)
EP (1) EP0686037B1 (es)
JP (1) JP3441459B2 (es)
KR (1) KR100248857B1 (es)
AT (1) ATE202281T1 (es)
AU (1) AU680239B2 (es)
BG (1) BG62383B1 (es)
BR (1) BR9406667A (es)
CA (1) CA2157003C (es)
CZ (1) CZ290562B6 (es)
DE (1) DE69427529T2 (es)
DK (1) DK0686037T3 (es)
ES (1) ES2159552T3 (es)
FI (1) FI953926A0 (es)
GR (1) GR3036649T3 (es)
HU (1) HU221169B1 (es)
NO (1) NO309456B1 (es)
NZ (1) NZ262657A (es)
PL (1) PL176796B1 (es)
PT (1) PT686037E (es)
RO (1) RO115115B1 (es)
RU (1) RU2139056C1 (es)
SK (1) SK282921B6 (es)
UA (1) UA43842C2 (es)
WO (1) WO1994018983A1 (es)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9301121A (es) 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.
US7704983B1 (en) 1992-03-02 2010-04-27 Eastern Virginia Medical School Antiprogestin method for reducing side effects associated with low dosage HRT and oral contraception
US6407082B1 (en) 1996-09-13 2002-06-18 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a vitamin D compound
DE19610635A1 (de) * 1996-03-11 1997-09-18 Schering Ag Sequentielle Estrogen/Progesteronantagonist-Kombination für die Hormonersatz-Therapie
AU5942700A (en) * 1996-03-11 2000-11-30 Schering Aktiengesellschaft Sequential estrogen/progestrone antagonist combination for hormone replacement theapy
US6511970B1 (en) 1996-09-13 2003-01-28 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of products that induce transforming growth factor-beta and/or apoptosis in the ovarian epithelium
US6034074A (en) 1996-09-13 2000-03-07 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of a Vitamin D compound
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US6765002B2 (en) 2000-03-21 2004-07-20 Gustavo Rodriguez Prevention of ovarian cancer by administration of products that induce transforming growth factor-β and/or apoptosis in the ovarian epithelium
US20060014728A1 (en) * 1996-11-21 2006-01-19 Kristof Chwalisz Hormone replacement therapy
US5855920A (en) * 1996-12-13 1999-01-05 Chein; Edmund Y. M. Total hormone replacement therapy
US7629334B1 (en) 1999-08-31 2009-12-08 Bayer Schering Pharma Aktiengesellschaft Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
CA2383659C (en) * 1999-08-31 2009-02-10 Jenapharm Gmbh & Co. Kg Mesoprogestins (progesterone receptor modulators) as a component of compositions for hormone replacement therapy (hrt)
US6432643B1 (en) 1999-10-22 2002-08-13 Duke University Method of determining Alzheimer's disease risk using apolipoprotein E4 genotype analysis in combination with decreased estrogen levels
US20040176336A1 (en) * 2000-03-21 2004-09-09 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20010044431A1 (en) * 2000-03-21 2001-11-22 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
US20050113351A1 (en) * 2000-03-21 2005-05-26 Rodriguez Gustavo C. Prevention of ovarian cancer by administration of products that induce biologic effects in the ovarian epithelium
EP1260225A1 (en) * 2001-05-18 2002-11-27 Pantarhei Bioscience B.V. A pharmaceutical composition for use in hormone replacement therapy
WO2002094276A1 (en) * 2001-05-18 2002-11-28 Pantarhei Bioscience B.V. Pharmaceutical composition for use in hormone replacement therapy
WO2002094278A1 (en) * 2001-05-23 2002-11-28 Pantarhei Bioscience B.V. Drug delivery system comprising a tetrahydroxylated estrogen for use in hormonal contraception
CA2448278C (en) * 2001-05-23 2010-06-08 Christian Franz Holinka Drug delivery system comprising a tetrahidroxilated estrogen for use in hormonal contraception
WO2003018026A1 (en) * 2001-08-31 2003-03-06 Pantarhei Bioscience B.V. Use of estrogenic compounds in combination with progestogenic compounds in hormone-replacement therapy
ES2278925T3 (es) * 2001-11-15 2007-08-16 Pantarhei Bioscience B.V. Uso de compuestos estrogenicos en combinacion con compuestos progestogenicos en terapias de sustitucion hormonal.
DE10206089A1 (de) 2002-02-13 2002-08-14 Zimmer Ag Bersteinsatz
ES2274252T3 (es) * 2002-06-11 2007-05-16 Pantarhei Bioscience B.V. Metodo de tratamiento o prevencion de desordenes de medicion inmune y formulacion farmaceutica para su uso en ellos.
ES2399423T3 (es) * 2002-06-11 2013-04-01 Pantarhei Bioscience B.V. Método para tratar la piel humana y una composición para el cuidado de la piel para su uso en tal método
WO2004006936A1 (en) * 2002-07-12 2004-01-22 Pantarhei Biosciences B.V. Pharmaceutical composition comprising estetrol derivatives for use in cancer therapy
CA2503549C (en) 2002-10-23 2012-07-10 Pantarhei Bioscience B.V. Pharmaceutical compositions comprising estetrol derivatives for use in cancer therapy
ATE340580T1 (de) * 2003-05-22 2006-10-15 Pantarhei Bioscience Bv Verwendung von zusammensetzungen enthaltend ein oestrogen zur behandlung und verhinderung von muskelskelettschmerzen
CA2673128C (en) * 2006-10-24 2018-07-03 Repros Therapeutics Inc. Compositions and methods for suppressing endometrial proliferation
EP2114412B1 (en) * 2007-01-08 2010-07-14 Pantarhei Bioscience B.V. Method of treating or preventing infertility in a female mammal and pharmaceutical kit for use in such method
US20080293683A1 (en) * 2007-05-24 2008-11-27 University Of Kansas Medical Center Hormone Replacement Therapy
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
JP2017516768A (ja) 2014-05-22 2017-06-22 セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. 天然の併用ホルモン補充療法剤及び療法
WO2016090139A1 (en) * 2014-12-03 2016-06-09 Evestra, Inc. Combination of estrogens plus antiprogestins with significant partial agonistic effect as an effective treatment of menopausal symptoms and for prevention of the occurrence of breast cancer
GEP20217243B (en) 2015-06-18 2021-04-26 Sprl Estetra Orodispersible dosage unit containing an estetrol component
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
EP3435977A4 (en) 2016-04-01 2019-10-16 Therapeuticsmd, Inc. PHARMACEUTICAL COMPOSITION OF STEROID HORMONE
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3890356A (en) * 1973-03-26 1975-06-17 Richardson Merrell Inc 7-Alkyl-{66 {hu 3,5{b -steroids
US3928398A (en) * 1973-11-01 1975-12-23 Richardson Merrell Inc Derivatives of 7{60 -methylestr-4-en-3{60 ,17{62 -diol
US4416822A (en) * 1982-07-09 1983-11-22 The Upjohn Company 17β-Difluoromethyl steroids
IL68222A (en) * 1983-03-24 1987-02-27 Yeda Res & Dev Contraceptive compositions comprising a progesterone antagonist and a blocker of progesterone activity
AU572589B2 (en) * 1983-12-14 1988-05-12 Upjohn Company, The 11(alpha)-difluoromethyl and (e)-and (z)-11-fluoromethylene steroids
MX9301121A (es) * 1992-03-02 1993-09-01 Schering Ag Metodo y equipo para la contracepcion oral y regulacion de la menstruacion con estrogeno/progestina/aniprogestina.

Also Published As

Publication number Publication date
AU6245494A (en) 1994-09-14
BG99880A (bg) 1996-02-28
NO953243L (no) 1995-08-17
KR960700727A (ko) 1996-02-24
GR3036649T3 (en) 2001-12-31
FI953926A (fi) 1995-08-22
SK104995A3 (en) 1997-04-09
CZ204895A3 (en) 1996-03-13
RO115115B1 (ro) 1999-11-30
DE69427529T2 (de) 2001-11-22
SK282921B6 (sk) 2003-01-09
PT686037E (pt) 2001-09-28
US5468736A (en) 1995-11-21
BR9406667A (pt) 1996-01-23
RU2139056C1 (ru) 1999-10-10
FI953926A0 (fi) 1995-08-22
CA2157003C (en) 2001-04-17
ATE202281T1 (de) 2001-07-15
PL176796B1 (pl) 1999-07-30
HUT72080A (en) 1996-03-28
JP3441459B2 (ja) 2003-09-02
CA2157003A1 (en) 1994-09-01
DE69427529D1 (de) 2001-07-26
PL310660A1 (en) 1995-12-27
HU9502306D0 (en) 1995-09-28
UA43842C2 (uk) 2002-01-15
NZ262657A (en) 1997-05-26
KR100248857B1 (ko) 2000-04-01
NO309456B1 (no) 2001-02-05
CZ290562B6 (cs) 2002-08-14
EP0686037A4 (en) 1997-11-26
BG62383B1 (bg) 1999-10-29
DK0686037T3 (da) 2001-08-27
EP0686037A1 (en) 1995-12-13
WO1994018983A1 (en) 1994-09-01
HU221169B1 (en) 2002-08-28
AU680239B2 (en) 1997-07-24
JPH08510993A (ja) 1996-11-19
EP0686037B1 (en) 2001-06-20
NO953243D0 (no) 1995-08-17

Similar Documents

Publication Publication Date Title
ES2159552T3 (es) Terapia de sustitucion de hormonas.
US5460820B1 (en) Method for providing testosterone and optionally estrogen replacement therapy to women
MY113079A (en) Estrogen agonists as remedies for cardiovascular diseases
MY125467A (en) Olanzapine dihydrate d
BG101349A (en) Combination of prostacyclin with an estrogen or progestin for the prevention and treatment of atherosclerotic vascular disease including preeclampsia and for the treatment of hypertension, and for hormone replacement therapy
PL327146A1 (en) Antagonists of the gonadotrophin liberating hormone
GB9003939D0 (en) Sulphatase inhibitors
BG101131A (en) 2-oxo-and 2-thio-1,2-dihydroquinolinyl-oxazolidinons
AU3436097A (en) Progestogen-anti-progestogen regimens
MY125565A (en) Intermediates and process for preparing olanzapine
EA199700449A1 (ru) Способ предотвращения остеопороза
ES2141044A1 (es) Terapia con oxibutinina.
SU1090083A1 (ru) Электронно-гидромеханическая система регулирования подачей топлива
HUP9701542A2 (hu) A prolaktinszintre semleges hatású 8,9-dehidroösztron ösztrogénként való alkalmazása
AU5110896A (en) Once-a-month-injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women
MX9709426A (es) Uso de alendronato para preparar composiciones para la prevencion de la osteoporosis.
JO1745B1 (en) Circuit scale
AU2003206424A1 (en) Sequential estrogen/progesterone antagonist combination for hormone replacement therapy
SU1223536A2 (ru) Установка для электронно-лучевой сварки
JO1813B1 (en) Slicing and forming cakes and covered with sesame

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 686037

Country of ref document: ES